Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome

被引：5
|
作者：
del-Pino, Rodrigo Aguirre [1 ,2 ]
Monahan, Rory C. [1 ,3 ]
Huizinga, Tom W. J. [1 ]
Eikenboom, Jeroen [4 ]
Steup-Beekman, Gerda M. [1 ,5 ]
机构：
[1] Leiden Univ Med Ctr, Dept Rheumatol, Leiden, Netherlands
[2] A Coruna Univ Hosp CHUAC, Div Rheumatol, Xubias Arriba 84, Galicia 15006, Spain
[3] Leiden Univ Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands
[4] Leiden Univ Med Ctr, Dept Internal Med, Div Thrombosis & Hemostasis, Leiden, Netherlands
[5] Haaglanden Med Ctr, Dept Rheumatol, The Hague, Netherlands
来源：
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2024年 / 50卷 / 06期
关键词：
antiphospholipid syndrome; antiphospholipid antibody; thrombosis; risk factor; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; VENOUS THROMBOEMBOLISM; SYNDROME SCORE; FOLLOW-UP; VITAMIN-D; CLASSIFICATION CRITERIA; CARDIOVASCULAR-DISEASE; CLINICAL-SIGNIFICANCE; RHEUMATOID-ARTHRITIS;
D O I：
10.1055/s-0043-1776910
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Persistence of serum antiphospholipid antibodies (aPL) is associated with a high thrombotic risk, both arterial and venous, and with pregnancy complications. Due to the potential morbidity and mortality associated with the presence of aPL, identifying and recognizing risk factors for the development of aPL and thrombosis in aPL carriers may help to prevent and reduce the burden of disease. Multiple elements are involved in the pathomechanism of aPL development and aPL-related thrombosis such as genetics, malignancy, and infections. This review will address the role of both well-known risk factors and their evolution, and of emerging risk factors, including COVID-19, in the development of aPL and thrombosis in aPL carriers.
引用
收藏
页码：817 / 828
页数：12
相关论文
共 50 条
  • [31] Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis.
    Sherer Y.
    Shoenfeld Y.
    Current Atherosclerosis Reports, 2001, 3 (4) : 328 - 333
  • [32] Stroke and Risk Factors in Antiphospholipid Syndrome
    Fan, Yangyi
    Xu, Yicheng
    Zhang, Sifan
    Song, Xiaodong
    Liu, Zunjing
    Tu, Wenjun
    Li, Chun
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (01):
  • [33] Cardiovascular Risk Factors in the Antiphospholipid Syndrome
    da Silva, Felipe Freire
    Levy, Roger Abramino
    de Carvalho, Jozelio Freire
    JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 2014
  • [34] Stroke and antiphospholipid syndrome—antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event
    Nataša Gašperšič
    Marjan Zaletel
    Jan Kobal
    Polona Žigon
    Saša Čučnik
    Snežna Sodin Šemrl
    Matija Tomšič
    Aleš Ambrožič
    Clinical Rheumatology, 2019, 38 : 379 - 384
  • [35] Risk factors of atherosclerosis and antiphospholipid syndrome
    Seredavkina, N. V.
    Reshetnyak, Tm.
    Alexandrova, E. N.
    Novikov, A. A.
    Nasonov, E. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 481 - 481
  • [36] Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome
    Barbhaiya, Medha
    Jannat-Khah, Deanna
    Levine, Jonah
    Costenbader, Karen
    Erkan, Doruk
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1357 - 1359
  • [37] Antiphospholipid Syndrome and Antibodies
    de Carvalho, Jozelio Freire
    Levy, Roger Abramino
    Shoenfeld, Yehuda
    JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 2014
  • [38] HELLP Syndrome and Its Relationship with Antiphospholipid Syndrome and Antiphospholipid Antibodies
    Appenzeller, Simone
    Souza, Fernando H. C.
    Silva de Souza, Alexandre Wagner
    Shoenfeld, Yehuda
    de Carvalho, Jozelio Freire
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (03) : 517 - 523
  • [39] Antiphospholipid antibodies and the antiphospholipid syndrome: Clinical significance and treatment
    Asherson, Ronald A.
    Cervera, Ricard
    Merrill, Joan T.
    Erkan, Doruk
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2008, 34 (03): : 256 - 266
  • [40] Antiphospholipid antibodies and coronary atherosclerosis: the antiphospholipid syndrome patients
    Plazak, W.
    Padjas, A.
    Celinska-Lowenhoff, M.
    Iwaniec, G.
    Swadzba, J.
    Luberda, T.
    Musial, J.
    Podolec, P.
    EUROPEAN HEART JOURNAL, 2013, 34 : 1013 - 1013
12345